文献速递临床试验与 GCP流行病学与生物统计

社区为基础的皮肤护理、过敏与湿疹评估(CASCADE):使用润肤剂预防特应性皮炎的一项随机对照试验方案

A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): an atopic dermatitis primary prevention study using emollients-protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2020-03-04

本研究为一项实用型、随机、医生盲法的初级保健试验,在未按风险筛选的婴儿中评估每日使用富含脂质润肤剂能否预防特应性皮炎(AD)。计划从四个实践研究网络招募婴儿-父母对并随机分入干预组或对照组(每组625名婴儿),随访24个月,主要结局为医生诊断AD的累积发病率。

要点

  • 在普通初级保健人群中评估润肤剂对AD的一级预防效果。
  • 采用实用型设计,无需研究访视,通过病历审查和问卷调查收集数据。
  • 主要结局为24个月内医生诊断AD的累积发病率。

核心结论

  • 若富含脂质润肤剂在普通人群中能有效降低AD患病率,可能改变婴儿常规皮肤护理的临床指导。

研究设计与样本

  • 实用型、随机、医生盲法的初级保健试验,从俄勒冈、科罗拉多、威斯康星和北卡罗来纳四个实践研究网络招募婴儿-父母对。
  • 符合条件者随机分入干预组(每日使用富含脂质润肤剂)或对照组(不使用润肤剂),每组625名婴儿,随访24个月。

关键数值与推荐

  • 主要结局为医生诊断AD的累积发病率,次要结局包括照护者报告的AD指标及其他特应性疾病的发生。
  • 数据分析采用意向性治疗原则,数据收集通过病历审查和问卷调查完成,无需研究访视。

临床怎么用

  • 在初级保健中,对未按风险筛选的婴儿,每日使用富含脂质润肤剂可能作为AD一级预防的候选干预措施。

局限性

  • 本研究为试验方案,尚未报告干预效果数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atopic dermatitis (AD) is a common, chronic skin disorder often beginning in infancy. Skin barrier dysfunction early in life serves as a central event in the pathogenesis of AD. In infants at high risk of developing AD, preventative application of lipid-rich emollients may reduce the risk of developing AD. This study aims to measure the effectiveness of this intervention in a population not selected for risk via a pragmatic, randomized, physician-blinded trial in the primary care setting. METHODS: Infant-parent dyads are recruited from a primary care practice participating through one of four practice-based research networks in Oregon, Colorado, Wisconsin, and North Carolina. Eligible dyads are randomized to the intervention (daily use of lipid-rich emollient) or the control (no emollient) group (n = 625 infants in each) and are followed for 24 months. The primary outcome is the cumulative incidence of physician-diagnosed AD and secondary outcomes include caregiver-reported measures of AD and development of other atopic diseases. Data collection occurs via chart review and surveys, with no study visits required. Data will be analyzed utilizing intention-to-treat principles. DISCUSSION: AD is a common skin condition in infants that affects quality of life and is associated with the development of other atopic diseases. If a safe intervention, such as application of lipid-rich emollients, in the general population effectively decreases AD prevalence, this could alter the guidance given by providers regarding routine skin care of infants. Because of the pragmatic design, we anticipate that this trial will yield generalizable results. TRIAL REGISTRATION: ClinicalTrials.gov: NCT03409367. Registered on 11 February 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Eichner B, Michaels LAC, Branca K, et al. A Community-based Assessment of Skin Care, Allergies, and Eczema (CASCADE): an atopic dermatitis primary prevention study using emollients-protocol for a randomized controlled trial. Trials. 2020. PMID: 32131885. doi:10.1186/s13063-020-4150-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。